Skip to content

Newsroom

type
year
Orion Pharma_Engineers_group image_1500x844.jpg

A technical career at Orion Pharma – Technical expertise is needed at every stage of medicine manufacturing

8/10/2026 We are Orion Pharma
Illustration image.png

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

8/10/2026 Stock exchange release
Illustration image.png

Orion Group Half-Year Financial Report January–June 2026

7/17/2026 Stock exchange release
Illustration image.png

Orion Corporation’s financial reporting and Annual General Meeting in 2027

7/17/2026 Stock exchange release
Illustration image.png

45,611 Orion Corporation A shares converted into B shares

7/15/2026 Stock exchange release
Illustration image.png

Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026

7/3/2026 Press release
Illustration image.png

Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market

6/30/2026 Press release
Illustration image.png

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

6/23/2026 Press release
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/18/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/17/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/16/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/15/2026 Flagging notifications
Orion Pharma_Veturi_100K Cancers_1500x844.jpg

The Veturi research ecosystem led by Orion: Personalised medicine is now advancing rapidly

6/15/2026 Science and Partnering
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/11/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/10/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/5/2026 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/1/2026 Flagging notifications
Illustration image.png

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

5/30/2026 Press release